Literature DB >> 1541971

The management of blepharospasm and hemifacial spasm.

J S Elston1.   

Abstract

The aetiology of blepharospasm and hemifacial spasm is different, but both produce involuntary eye closure and facial movements which do not respond to systemic drug treatment. The introduction of therapeutic focal muscle weakening with botulinum toxin injections in the early 1980s appeared to offer great promise in the management of these conditions. In this paper the results of botulinum toxin treatment of 234 patients with blepharospasm and 73 patients with hemifacial spasm over a 7-year period have been analysed. Most patients receive sustained benefit from repeated injections whilst side-effects become less frequent. A clinically recognisable subgroup of patients with blepharospasm respond poorly and may be better treated surgically.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1541971     DOI: 10.1007/bf00839203

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  11 in total

1.  Essential blepharospasm.

Authors:  A C Bird; W I McDonald
Journal:  Trans Ophthalmol Soc U K       Date:  1975-07

2.  Botulinum toxin therapy for involuntary facial movement.

Authors:  J S Elston
Journal:  Eye (Lond)       Date:  1988       Impact factor: 3.775

3.  Pathophysiology of blepharospasm and oromandibular dystonia.

Authors:  A Berardelli; J C Rothwell; B L Day; C D Marsden
Journal:  Brain       Date:  1985-09       Impact factor: 13.501

4.  Microvascular decompression of the facial nerve for hemifacial spasm: clinical and electrophysiologic observations.

Authors:  R G Auger; D G Piepgras; E R Laws; R H Miller
Journal:  Neurology       Date:  1981-03       Impact factor: 9.910

5.  Hemifacial spasm. Results of unilateral myectomy.

Authors:  P E Garland; J R Patrinely; R L Anderson
Journal:  Ophthalmology       Date:  1987-03       Impact factor: 12.079

6.  Effect of treatment with botulinum toxin on neurogenic blepharospasm.

Authors:  J S Elston; R W Russell
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-22

7.  Primary hemifacial spasm: a neurophysiological study.

Authors:  A Esteban; P Molina-Negro
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-01       Impact factor: 10.154

8.  Blepharospasm: a review of 264 patients.

Authors:  F Grandas; J Elston; N Quinn; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

9.  The significance of ophthalmological symptoms in idiopathic blepharospasm.

Authors:  J S Elston; C D Marsden; F Grandas; N P Quinn
Journal:  Eye (Lond)       Date:  1988       Impact factor: 3.775

10.  Ipsilateral blepharospasm and contralateral hemidystonia and parkinsonism in a patient with a unilateral rostral brainstem-thalamic lesion: structural and functional abnormalities studied with CT, MRI, and PET scanning.

Authors:  K L Leenders; R S Frackowiak; N Quinn; D Brooks; D Sumner; C D Marsden
Journal:  Mov Disord       Date:  1986       Impact factor: 10.338

View more
  15 in total

1.  Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs.

Authors:  A R Bentivoglio; A Fasano; T Ialongo; F Soleti; S Lo Fermo; A Albanese
Journal:  Neurotox Res       Date:  2009-02-24       Impact factor: 3.911

Review 2.  Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases.

Authors:  S Jitpimolmard; S Tiamkao; M Laopaiboon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-06       Impact factor: 10.154

3.  Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport.

Authors:  Katja Kollewe; Bahram Mohammadi; Reinhard Dengler; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2010-05-01       Impact factor: 3.575

4.  Validation of the Hemifacial Spasm Grading Scale: a clinical tool for hemifacial spasm.

Authors:  Nicola Tambasco; Simone Simoni; Elisa Sacchini; Paolo Eusebi; Erica Marsili; Pasquale Nigro; Elona Brahimi; Federico Paolini Paoletti; Michele Romoli; Paolo Calabresi
Journal:  Neurol Sci       Date:  2019-05-10       Impact factor: 3.307

Review 5.  Botulinum toxin in hemifacial spasm: the challenge to assess the effect of treatment.

Authors:  Bettina Wabbels; Peter Roggenkämper
Journal:  J Neural Transm (Vienna)       Date:  2012-01-10       Impact factor: 3.575

6.  Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study.

Authors:  N Hyman; M Barnes; B Bhakta; A Cozens; M Bakheit; B Kreczy-Kleedorfer; W Poewe; J Wissel; P Bain; S Glickman; A Sayer; A Richardson; C Dott
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-06       Impact factor: 10.154

7.  Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.

Authors:  G L Sheean; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-12       Impact factor: 10.154

8.  HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness.

Authors:  H S Markus; D C Costa; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-02       Impact factor: 10.154

Review 9.  Hemifacial spasm: a prospective long-term follow up of 83 cases treated by microvascular decompression at two neurosurgical centres in the United Kingdom.

Authors:  R D Illingworth; D G Porter; J Jakubowski
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-01       Impact factor: 10.154

10.  Experience with long-term treatment with albumin-supplemented botulinum toxin type A.

Authors:  Bahram Mohammadi; Katja Kollewe; Maresa Wegener; Hans Bigalke; Reinhard Dengler
Journal:  J Neural Transm (Vienna)       Date:  2009-03-25       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.